Martin Bornhäuser

Research interests

Publications

• Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 –Internal Tandem Duplication Mutation (SORMAIN)

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.03345

• Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30580-1

• Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2018.79.2184

• Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation

  Science Translational Medicine · 2017 · https://doi.org/10.1126/scitranslmed.aam7828

• Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00362-9

• Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

  Transplantation and Cellular Therapy · 2014 · https://doi.org/10.1016/j.bbmt.2014.10.021

• Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1309533

• Multiple myeloma

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(14)60493-1

• Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

  Blood Cancer Journal · 2014 · 10.1038/bcj.2014.39

• Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70349-2

• The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  Nature Reviews Clinical Oncology · 2012 · https://doi.org/10.1038/nrclinonc.2012.150

• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.234

• Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

  Blood · 2011 · https://doi.org/10.1182/blood-2011-01-329821

• Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

  Bone Marrow Transplantation · 2011 · 10.1038/bmt.2011.69

• Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.32.8500

• Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro

  Haematologica · 2010 · 10.3324/haematol.2009.010736

• Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70225-6

• Immunomodulatory Properties of Mesenchymal Stromal Cells and Their Therapeutic Consequences for Immune-Mediated Disorders

  Stem Cells and Development · 2009 · 10.1089/scd.2009.0345

• Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

  Blood · 2009 · https://doi.org/10.1182/blood-2009-07-234880

• Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

  Bone Marrow Transplantation · 2008 · https://doi.org/10.1038/bmt.2008.316

• Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.11.6053

• Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro

  Stem Cells · 2004 · https://doi.org/10.1634/stemcells.22-3-377

• Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.12.011

• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

  Blood · 2002 · https://doi.org/10.1182/blood.v99.12.4326

• Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection

  Bone Marrow Transplantation · 1999 · 10.1038/sj.bmt.1701779

Current projects

No projects listed.